Namilumab

N/A

Report date: 2025/04/25 20:01:23

Base Information

Drug NameNamilumab
Drug Alias NameAMG-203MT-203IZN-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionMacrophage colony stimulating factor 2 inhibitors
TargetsMacrophage colony stimulating factor 2
Therapy Area/IndicationsPlaque psoriasisAxial SpondyloarthritisSarcoidosis, Pulmonary +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[15] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen IncTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKinevant Sciences GmbhIzana Bioscience LtdTakeda Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsPlaque psoriasisAxial SpondyloarthritisSarcoidosis, Pulmonary +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia